X Pan1, T Lv1, F Zhang1, H Fan1, H Liu2, Y Song3. 1. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu, China. 2. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu, China. netlhb@126.com. 3. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu, China. yong_song6310@yahoo.com.
Abstract
BACKGROUND: The subgroup of young patients with non-small-cell lung cancer (NSCLC) is poorly understood. We retrospectively studied the clinical characteristics, gene mutations, and outcomes of patients with NSCLC (aged ≤ 40 years). RESULTS: Of the 7494 patients with lung cancer diagnosed from February 2001 to October 2016, 252 aged ≤ 40 years showed NSCLC. We divided their cases into non-squamous cell carcinoma and squamous cell carcinoma groups according to their histology results. Of the 252 young NSCLC patients, 173 (69%) patients had stage IIIB or IV, and 196 (78%) had never smoked. The four most common metastases were intrapulmonary lesions, pleura, bone, and brain. Among patients with adenocarcinoma, 29 (40%, n = 73) harbored epidermal growth factor receptor (EGFR) mutations, 25 (34%, n = 74) harbored anaplastic lymphoma kinase (ALK) translations, and 1 (14%, n = 7) harbored ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) translations. The median progression-free survival (PFS) and overall survival (OS) were 3.3 and 27.6 months for patients receiving chemotherapy (n = 65), and 12.1 and 33.6 months for patients receiving EGFR tyrosine kinase inhibitors (TKIs) (n = 13), respectively. Patients receiving crizotinib had a median PFS time of 21.9 months (n = 8). CONCLUSIONS: Young patients are associated with an increased likelihood of gene mutations and can receive a better prognosis when patients harboring gene mutations are treated with EGFR-TKIs or ALK inhibitors.
BACKGROUND: The subgroup of young patients with non-small-cell lung cancer (NSCLC) is poorly understood. We retrospectively studied the clinical characteristics, gene mutations, and outcomes of patients with NSCLC (aged ≤ 40 years). RESULTS: Of the 7494 patients with lung cancer diagnosed from February 2001 to October 2016, 252 aged ≤ 40 years showed NSCLC. We divided their cases into non-squamous cell carcinoma and squamous cell carcinoma groups according to their histology results. Of the 252 young NSCLCpatients, 173 (69%) patients had stage IIIB or IV, and 196 (78%) had never smoked. The four most common metastases were intrapulmonary lesions, pleura, bone, and brain. Among patients with adenocarcinoma, 29 (40%, n = 73) harbored epidermal growth factor receptor (EGFR) mutations, 25 (34%, n = 74) harbored anaplastic lymphoma kinase (ALK) translations, and 1 (14%, n = 7) harbored ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) translations. The median progression-free survival (PFS) and overall survival (OS) were 3.3 and 27.6 months for patients receiving chemotherapy (n = 65), and 12.1 and 33.6 months for patients receiving EGFR tyrosine kinase inhibitors (TKIs) (n = 13), respectively. Patients receiving crizotinib had a median PFS time of 21.9 months (n = 8). CONCLUSIONS: Young patients are associated with an increased likelihood of gene mutations and can receive a better prognosis when patients harboring gene mutations are treated with EGFR-TKIs or ALK inhibitors.
Authors: Y-L Wu; C Zhou; C-K Liam; G Wu; X Liu; Z Zhong; S Lu; Y Cheng; B Han; L Chen; C Huang; S Qin; Y Zhu; H Pan; H Liang; E Li; G Jiang; S H How; M C L Fernando; Y Zhang; F Xia; Y Zuo Journal: Ann Oncol Date: 2015-06-23 Impact factor: 32.976
Authors: Matthew S Lara; Ann Brunson; Ted Wun; Ben Tomlinson; Lihong Qi; Rosemary Cress; David R Gandara; Karen Kelly Journal: Lung Cancer Date: 2014-05-06 Impact factor: 5.705
Authors: Marco Galvez-Nino; Rossana Ruiz; Joseph A Pinto; Katia Roque; Raul Mantilla; Luis E Raez; Luis Mas Journal: Lung Date: 2019-11-26 Impact factor: 2.584
Authors: Barbara J Gitlitz; Silvia Novello; Tiziana Vavalà; Marisa Bittoni; Alicia Sable-Hunt; Dean Pavlick; Robert Hsu; S Lani Park; Ruthia Chen; Matthew Cooke; Amy Moore; Alexa B Schrock; Joan H Schiller; Bonnie J Addario; Geoffrey R Oxnard Journal: JTO Clin Res Rep Date: 2021-05-24